Komipharm International
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Komipharm International is a South Korean pharmaceutical company that develops and supplies medicinal products.
Its customers are broadly within the health-care supply chain, including distributors, clinics, and other medical institutions. The company is listed on KOSDAQ, South Korea's technology and small-cap stock exchange.
Summary is AI-generated and may contain errors · figures from DART filings
Komipharm International in five facts
What does Komipharm International do?
Komipharm International is a South Korean pharmaceutical company that develops and supplies medicinal products.
Where is Komipharm International listed and in which sector?
Komipharm International (Korean name: 코미팜) trades under KRX code 041960 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Komipharm International?
Its market capitalisation was US$535.6M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Komipharm International's latest annual revenue and operating profit?
For fiscal year 2025, Komipharm International reported revenue of US$39.6M, operating profit of US$1.5M and a net loss of US$6.1M, per its annual report on DART (data retrieved from DART on 2026-09-08). Revenue was down 10.7% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-08
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- [Amended] Supply contract signed
Komipharm International updated a previously disclosed supply contract with the Public Procurement Service, now worth US$4.51M, about 10.33% of its recent annual revenue, running through Sep 2027.
Supply contract · Sep 10 - [Amended] Supply contract signed
Komipharm International updated a previously disclosed supply contract with the Public Procurement Service, now worth US$6.82M, about 25.33% of its recent annual revenue, running through Nov 2027.
Supply contract · Apr 8 - [Amended] Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Komipharm International updated its previously filed consolidated results for FY2025: revenue of US$35.6M (−10.74% year on year), operating profit of US$1.33M (−68.34% year on year) and a net loss of US$5.45M (from a profit a year earlier).
Earnings · Mar 11 · 2 versions - Treasury share acquisition: results reportTreasury Shares · Feb 6
- [Amended] Supply contract signedSupply contract · Jan 9